r/valueinvesting
What am I missing with Canon (7751)?
Canon is undervalued at ~10x P/E with surging FCF (+76% YoY) and hidden growth in medical imaging & semiconductor lithography.
- Strong valuation metrics with ~10x forward P/E and robust free cash flow generation.
- Significant 76% year-over-year increase in free cash flow indicates improving operational health.
- Diversification into high-growth medical systems and semiconductor lithography reduces reliance on legacy printing.
- Market perception of Canon as a no-growth legacy hardware company may persist despite diversification efforts.
- Exposure to cyclical industrial and semiconductor equipment markets introduces potential volatility.
I’ve been looking at Canon (TSE: 7751 / NYSE: CAJ) recently and think it’s an interesting value opportunity that doesn’t get discussed much outside Japan.
The market is valuing Canon like a no-growth legacy hardware company.
Yet the stock trades at only \~10x forward earnings and \~6x forward EV/EBITDA while generating hundreds of billions of yen in annual operating cash flow.
Most investors still view Canon as a mature camera and printer company. While those businesses remain important, today’s Canon is substantially more diversified than that perception suggests.
The company is organized around four major segments:
\- Printing
\- Imaging
\- Medical
\- Industrial
What initially attracted me was the free cash flow profile.
According to Canon’s FY2024 Annual Report, free cash flow increased from ¥175.8 billion in FY2023 to ¥309.5 billion in FY2024, a 76% increase year-over-year. For a company of Canon’s size and maturity, that’s a meaningful jump and suggests the underlying business may be healthier than the market gives it credit for. (Canon Global)
The diversification story is also interesting.
Medical has become a significant business through Canon Medical Systems, which competes in CT, MRI, ultrasound, X-ray and healthcare IT. This is a much more attractive end market than traditional office printing and gives Canon exposure to long-term growth in medical imaging. (Canon Medical)
The Industrial segment is another underappreciated asset. Canon operates in semiconductor lithography, display manufacturing equipment and other industrial technologies. Management has spent years investing in these areas rather than simply harvesting the legacy printing franchise. (Canon(Japan))
One thing I like is that the thesis does not require a heroic growth assumption.
There is a lot of discussion around Canon’s nanoimprint lithography technology. I do not own the stock because I think it will become another ASML. The probability of that outcome seems low.
However, if nanoimprint lithography achieves meaningful commercial adoption, there could be substantial upside that is not reflected in the current valuation. I view this as optionality rather than the core thesis.
The core thesis is much simpler:
\- Strong and improving free cash flow
\- Diversified business mix
\- Exposure to medical imaging and industrial technology
\- Shareholder returns through dividends and buybacks
\- Valuation that appears low relative to profitability and cash generation
Risks obviously remain. Printing is still a large contributor to profits, some businesses are cyclical, and Canon has a long history of trading at low multiples.
My question for the sub:
What am I missing?
Why should a company generating over ¥300 billion in annual free cash flow, with meaningful positions in medical imaging and industrial technology, deserve such a modest valuation multiple?
Good writeup, and the cash-flow framing is fair. The main thing I'd push on: the FCF you're anchoring to is FY2024, and the recent trajectory has rolled over. In its April 2026 report Canon missed EPS by \~28% on margin pressure (stock fell \~9%), cut full-year guidance, and the most recent quarter's free cash flow was actually negative. So the +76% jump looks more like a peak than a new trend, and a chunk of that low multiple is the market pricing margin deterioration your FY2024-based thesis doesn't capture yet.
The other pieces of "why so cheap":
- Printing is still a big share of profit and it's in structural decline, not a cyclical dip — a melting-ice-cube cash cow, so the FCF it throws off gets discounted.
- A lot of recent reported strength was weak-yen tailwind, which reverses if the yen firms, and you're not really paid for that FX risk.
- Medical and Industrial are real but small vs the legacy base, and up against GE/Siemens/Philips and ASML/Nikon. NIL is genuine optionality (you framed it right), not a needle-mover yet.
Honest bear answer to "what am I missing": it's cheap for understandable reasons — low growth (street \~6-7%, below the JP market), structural printing decline, now softening margins — and it's been a perennial low-multiple name. The DCF gap is real, but value here needs a catalyst. What actually re-rates it — capital return stepping up, a governance/efficiency push, or NIL hitting? Without one, cheap tends to stay cheap.
Appreciate the thoughtful pushback. I think most of your bear points are valid.
I agree that anchoring too heavily on FY2024 FCF can be misleading. The recent margin deterioration, earnings miss, and guidance cut are all real and deserve to be reflected in the thesis. I also agree that printing remains a much larger contributor to profits than many bulls (including myself) sometimes imply.
That said, I’m not sure I’d go as far as calling FY2024 FCF a clear peak yet.
Management is still guiding to roughly ¥330bn of FCF for FY2026 despite the weaker operating environment. Obviously guidance isn’t reality, but it suggests management itself does not view FY2024 as a one-off cash flow outlier.
I also largely agree on the “why is it cheap?” question. Structural printing decline, FX exposure, and low expected growth are all legitimate reasons for a discounted multiple.
Where I may differ is on how much of that is already reflected in valuation.
At roughly ~10x earnings, ~1.1x book, and around ~6x EV/EBITDA, the market appears to be assuming that the legacy businesses dominate the future economics of the company. My view is that Medical and Industrial do not need to become dominant segments to create value; they simply need to become a larger share of profits over time while the company continues returning capital.
On NIL, we’re in complete agreement. I view it as optionality rather than part of the base case.
The point I find most interesting is actually your catalyst question. If the stock is genuinely cheap, what closes the gap?
My current answer would be some combination of:
- Continued buybacks and capital returns
- Sustained ¥300bn+ FCF generation
- Medical and Industrial becoming a larger percentage of profits
- Evidence that printing declines remain manageable rather than accelerating
Without one of those, I agree that Canon risks remaining a perennial low-multiple stock.
One question I’d have for you: what multiple do you think Canon deserves if it can sustainably generate ~¥300bn+ annual FCF while maintaining current capital return policies? That’s where I’m struggling to reconcile the valuation with the fundamentals.
Huh? Why was this guy‘s comment deleted?
Good question, and it's the right one, because the multiple basically collapses into one variable: how durable that FCF is.
\~10x is fair for FCF the market thinks is flat-to-declining, which is what it's pricing. Rough math: for a mature Japanese industrial you'd want \~9-10% return, so flat \~¥300bn FCF is worth \~10-11x; a durable +2-3% gets you \~13-14x; a structural -2% argues \~8-9x. So 10x isn't the market being dumb, it's the market saying Medical + Industrial growth just offsets printing's decline and no more, and the April miss + guidance cut made it more confident in that flat-to-down read.
But here's where I'd push back on my own bear case: the strongest part of your thesis isn't a re-rating, it's that you may not need one. If Canon holds ¥300bn+ FCF and keeps buying back stock and paying the dividend, you compound \~8-10% a year at a permanently cheap multiple. You win at 10x.
So the bet isn't "10x → 14x," it's "the FCF holds." If the ¥330bn FY2026 guide is real and printing declines stay gradual, you get paid well while you wait, with the mix-shift and NIL as free optionality. What breaks it isn't a low multiple, it's FCF eroding faster than buybacks can offset.